Sun Pharmaceutical announced interim results from a Phase 2 study of interleukin-23 (IL-23) inhibitor ILUMYA™ (tildrakizumab-asmn) in patients with active psoriatic arthritis. The interim analysis revealed that over 71 percent of patients treated with ...